PCI Biotech Announces Employee Share Option Scheme
PCI Biotech has taken a significant step by granting share options to key employees, reinforcing its commitment to employee incentives. This decision follows the authorization from the recent Annual General Meeting and aligns with the company's remuneration policy.
Details of the Share Options Granted
The Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 885,000 share options to key employees. Each option grants the holder the right to subscribe for or acquire one share at a strike price of NOK 1.81. This price is based on the volume-weighted average share price (VWAP) calculated over the five trading days preceding the grant date. The options come with no upfront cost and will vest over a three-year period, with the final vesting scheduled for the third quarter of 2029.
Assessment of Share Options
According to the remuneration policy, the Board aims to allocate a number of options that hold a fair value during the allotment process. This valuation uses the Black-Scholes model, taking into account the annual base salary of each employee. Additionally, the Board considers factors such as the balance between short- and long-term performance-based rewards, the current values of previously held options, overall company performance, job responsibilities, and the importance of retaining key positions.
Vesting and Long-term Ownership
To promote long-term ownership among executive management, shares acquired through exercising these options must be held for at least one year. However, there is an exception that allows shares to be sold immediately to cover transaction costs and taxes through a cash-less exercise arrangement. This long-term incentive program encourages executives to build and maintain share ownership valued at least equal to their one-year gross salary, thereby enhancing their commitment to the company's future.
Distribution of Share Options to Executives
A total of 530,000 of the granted options have been allocated to primary insiders. Notably, Ronny Skuggedal, the CEO and CFO, has received 400,000 options, bringing his total to 1,020,000 unexercised share options along with 55,000 shares. Similarly, Anders Høgset, the Chief Scientific Officer (CSO), has been awarded 130,000 options, totaling 460,000 unexercised options and 64,800 shares after the allocation.
Authorized Share Option Limits
The current authorization from the Annual General Meeting permits a maximum of 2,790,000 share options. To date, the Board has granted 2,388,334 options, clearly aiming to motivate employees to align their interests with those of shareholders.
Contact Information
For more information, please contact Ronny Skuggedal, CEO, via email at rs@pcibiotech.no or on his mobile at +47 9400 5757.
Frequently Asked Questions
What is the purpose of the share option scheme?
The share option scheme is designed to incentivize key employees by aligning their interests with those of shareholders, thereby motivating long-term performance.
How many share options were granted in total?
In total, 885,000 share options have been granted to key employees at PCI Biotech.
What is the vesting period for the options?
The share options will vest evenly over a three-year period, concluding by the third quarter of 2029.
Who are the primary beneficiaries of this grant?
Ronny Skuggedal, the CEO, and Anders Høgset, the CSO, are the primary beneficiaries, having received substantial allocations of options.
What are the tax implications for employees exercising options?
Employees can sell shares acquired from exercising options to cover transaction costs and taxes, benefiting from a cash-less exercise arrangement.
